- [Peter] Hi, I'm Peter Soltani, senior vice president at Beckman Coulter Diagnostics.
- [Itai] And I'm Itai Hayut, I'm the co-founder and CEO of Scopio Labs.
- As part of Beckman Coulter's reimagining healthcare, we're thrilled to announce this partnership with Scopio Labs. They bring to us very innovative technology that really changes the game, brings tremendous benefits to our customers, and really addresses many of their pain points today in the lab.
And we feel that the technology provides a tremendous runway for many innovations to come in the future.
- So Scopio Labs have developed AI-powered workflow solution for hematology labs. Basically, what we're able to do is to develop a technology that can scan and digitize microscopy slides, specifically, peripheral blood smears and other hematology samples, right? And by doing so, we actually provide not only snapshots of individual cells, but actually a huge area of the sample.
So, it's not just a semi-digital solution, but it's a complete digital transformation for the hematology lab and the way laboratory experts are reviewing peripheral blood smears. The two main value proposition we bring to hematology labs using our digital technology is, the first one is we use AI to pre-classify the cells, right? And in this way, we enable to do the work much more efficiently and much more consistently, right?
The other value proposition is by detaching the need for the expert and the sample to be in the same location, we enable remote work, right? So, for example, hub and spoke model, one expert can review a different location samples that are created in a different lab.
- We're thrilled to be here at AACC, and the benefits that my friend Itai outlined of the product, we're thrilled to see that they've been validated by the tremendous response we've seen by customers here at a AACC. And we look forward to bringing this great technology to our customers.